CD274 and neoplasm: Notably, preclinical studies suggested that combining these nanoparticles with anti–PD-L1 enhanced tumor control and delineated a promising therapeutic approach using anti–PD-L1–conjugated nanocarriers for aggressive CRC (Júnior et al., 2023).